Introduction
HANGZHOU SUNLIGHT BIOMATERIALS CO., LTD. (杭州深蓝生物材料有限公司) is a Chinese biomaterials company founded in August 2020 that focuses on the research, production, and sale of specialty engineering plastics, especially polysulfone resins and polyurethane two-component sealants for medical applications. The company’s stated core market is the medical device sector, with particular emphasis on hemodialyzer applications, where it positions its products as domestically developed alternatives to internationally established materials.
In the plastics industry, the company sits at the intersection of high-performance polymers, medical consumables, and localized supply-chain substitution. Its reported product set includes polysulfone, polyethersulfone, and polyurethane sealing adhesives, which are used in demanding filtration and biomedical environments that require chemical resistance, thermal stability, and biocompatibility. Publicly available materials indicate that the company is building technical capabilities in polyarylsulfone synthesis, medical-grade adhesive formulation, and small-scale industrial production, while also pursuing intellectual property development and collaboration with Chinese universities.
The company has described its mission as supporting the domestic development of materials used in blood dialysis equipment and related filtration membranes, an area where imported specialty polymers have historically played a major role. As of the latest available public information, it operates a 1,500-square-meter research and business center in Hangzhou’s Zijin Port Science and Technology City and a production base in Jiande High-tech Industrial Park in Zhejiang Province.
History and Development
Founded in 2020, Hangzhou Sunlight Biomaterials is a relatively young entrant in China’s specialty polymer field. Its early strategy centered on developing proprietary know-how for polysulfone industrial synthesis, a technically demanding process that requires precise control of reaction conditions and material performance.
A first development milestone was the company’s accumulation of intellectual property: public information states that it has been granted four utility model patents, has one published invention patent, and has three patent applications under review. A later patent record also shows a 2024 patent application for a preparation method of polyarylsulfone resin, suggesting continued process-development activity in the same polymer family.
A second milestone is the company’s move from laboratory and formulation work toward practical medical-device validation. According to public disclosures, its polyurethane sealant has already been used in volume by multiple firms in different hemodialyzer designs and has passed biological evaluation tests relevant to hemodialysis equipment.
A third milestone is the transition to pilot-scale polymer production. The company reports that its polysulfone material has reached stable small-batch production in a 100-liter reactor and has undergone multiple spinning trials for hemodialysis membranes and tangential flow filtration membranes, with performance described as comparable to imported materials.
Business Operations and Segments
The company’s business is centered on two closely related segments:
- Specialty engineering plastics
- Medical-device auxiliary materials, especially sealants and membrane-related polymers
Its public profile indicates a focus on research, production, and sales rather than broad downstream processing or consumer plastics. The business model appears specialized and application-driven, serving the medical filtration supply chain rather than mass-market plastic products.
The company also reports collaboration with institutions such as Zhejiang University, Jilin University, and East China University of Science and Technology, reflecting an R&D-led operating model. That pattern is consistent with the technical demands of medical-grade polysulfone development, where polymer purity, reproducibility, and process control are critical.
Products and Technologies
Main product classes
| Product | Likely industrial role | Reported application focus |
|---|---|---|
| Polysulfone (PSU) | High-performance thermoplastic | Hemodialysis membranes, filtration materials |
| Polyethersulfone (PESU) | High-performance thermoplastic | Medical filtration and related membrane uses |
| Polyurethane two-component sealant | Reactive adhesive/sealant system | Hemodialyzer sealing and assembly |
The most technically significant part of the company’s portfolio is its work on polyarylsulfone materials, a class that includes polysulfone and polyethersulfone. These polymers are valued in medical and filtration applications because they combine thermal resistance, hydrolytic stability, and processability suitable for membrane spinning and device assembly.
Public information indicates that the company has already developed a mature formula and claims to control key industrial synthesis steps and process parameters for polysulfone production. It also reports that the material has been tested in spinning trials for blood dialysis membranes and tangential flow filtration membranes, both of which are technically demanding applications requiring consistent pore formation and material integrity.
Its polyurethane sealant is described as having been used in several hemodialyzer configurations and having passed biological evaluation tests tied to those devices. In practical terms, this suggests the company is not only producing base polymer resins but also supplying a complementary material used in device integration.
Applications and End Markets
The company’s principal end market is the medical device industry, especially:
- Hemodialyzers
- Blood dialysis membranes
- Tangential flow filtration membranes
- Medical device sealing and assembly materials
These applications place the company in a segment where material specifications are unusually strict. In dialysis and filtration products, manufacturers typically require polymers that can maintain performance under sterilization and prolonged exposure to fluids, while also meeting biocompatibility expectations. The company’s disclosures emphasize that its products are intended to match the performance of foreign comparable materials in these settings.
Its market positioning is therefore tied to import substitution in high-end medical polymers, a theme that has broader relevance in China’s advanced materials sector.
Global Presence and Market Position
Publicly available information suggests that Hangzhou Sunlight Biomaterials remains a small-scale specialist company rather than a large multinational plastics producer. Its publicly disclosed workforce is around 30 employees, and its production is still described as small-batch rather than mass-scale.
There is no reliable public evidence in the provided sources of global subsidiaries, overseas factories, or major export networks. Its market position appears concentrated in China’s medical materials ecosystem, where it serves a niche but technically important role.
The company has also been listed in an industry exhibitor database associated with ChinaPlas/Plas exhibitor information, reinforcing its presence within the plastics and polymer manufacturing community, although the available exhibitor listing information is limited in the supplied material.
Sustainability and Environmental Initiatives
The company’s public materials do not describe a broad sustainability program in the manner of large multinational chemical producers. Its principal environmental relevance is indirect: by developing domestic alternatives for imported specialty polymers, it may contribute to shorter supply chains and potentially reduce some logistics-related impacts.
At the same time, its core products are high-performance synthetic polymers used in medical devices, so environmental considerations remain tied to broader industry questions about resource use, process efficiency, and end-of-life management. No public information in the supplied sources indicates formal recycling, carbon-reduction, or lifecycle-assessment programs.
Financial Performance and Economic Impact
No audited financial statements or revenue figures were provided in the available sources, so the company’s financial performance cannot be reliably quantified here. On the basis of public disclosures, its economic significance lies less in scale than in technology substitution and supply-chain localization.
Its work on polysulfone and medical sealants is relevant to China’s domestic capacity building in medical-grade materials, a segment that can influence procurement resilience for dialysis and filtration equipment manufacturers. The company’s collaboration with universities and pursuit of patents also indicate a role in applied materials innovation rather than commoditized plastics production.
Leadership and Corporate Governance
The available sources do not provide a verified management roster, board structure, or detailed governance disclosures. As a result, leadership assessment must remain limited to the company’s institutional strategy as reflected in its public materials: R&D-centered development, university collaboration, and patent-driven technology building.
Innovations and Future Outlook
The company’s future development appears to depend on three factors:
- Scaling polyarylsulfone resin production beyond pilot and small-batch levels
- Expanding qualification of its materials in medical filtration and hemodialysis applications
- Converting patent activity and university partnerships into broader industrial adoption
Its appearance in a national-level biomedical materials shortlist for medical polysulfone suggests that the company is recognized within China’s broader innovation ecosystem for this material category. That recognition may support further development, especially if it can demonstrate consistent quality, regulatory conformity, and cost-performance competitiveness against imported alternatives.
Summary
Hangzhou Sunlight Biomaterials is a focused Chinese specialty materials company working in high-performance polysulfone-based polymers and medical-grade polyurethane sealants for dialysis and filtration applications. Its significance in the plastics industry lies in its attempt to build domestic capability in a technically demanding niche where material purity, reproducibility, and biocompatibility are essential.
References
- •
CPS+ eMarketplace. (n.d.). HANGZHOU SUNLIGHT BIOMATERIALS CO., LTD.HANGZHOU SUNLIGHT BIOMATERIALS CO., LTD.. CPS+ eMarketplace. https://www.chinaplasonline.com/eMarketplace/ExhibitorInfo?CompId=1021185Link